JnJ completes acquisition of Halda Therapeutics, its novel platform for cancer treatment
New Brunswick: Johnson & Johnson has announced the successful completion of its acquisition of Halda Therapeutics OpCo, a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC)…